Janux Therapeutics, Inc. JANX R2KR3KPHARMA
Company Overview
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Recent Developments
- Dec 2025 Revenue of $10.00M (-5.6% YoY); net profit $-113.62M.
- Trailing 12 Months Year-on-year growth — revenue -5.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -5.55% |
Stock Price Performance
| 1 Year: | -33.25% |
| 6 Months: | +10.99% |
| 3 Months: | +7.00% |
| 1 Month: | -0.12% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)44.92 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 52.0% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | JANX Janux Therapeutics, Inc. R2KR3KPHARMA | 16.66 | -10.16 | $1.02B | 0.00% | -16.15% | -10.70% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 380.00K | 482.00K | 1.16M | 1.59M | 2.37M | 1.81M | 2.05M | 1.06M | 2.52M | 1.25M | 8.90M | 439.00K | 0 | 0 | 10.00M | 0 | 3.73M | 10.27M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.90M | 45.12M | 45.25M | 42.40M | 37.95M | - |
| Operating Income | -1.11M | -1.26M | -2.28M | -6.25M | -10.90M | -13.54M | -17.26M | -18.02M | -20.28M | -20.75M | -15.81M | -20.16M | -13.82M | -35.84M | -34.90M | -45.12M | -35.25M | -42.40M | -34.21M | -31.69M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.38M | -44.58M | -34.75M | -41.93M | -33.74M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -23.51M | -33.86M | -24.31M | -31.95M | -24.36M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.46M | -1.26M | -2.28M | -6.21M | -10.77M | -13.41M | -16.89M | -16.70M | -17.46M | -17.51M | -11.57M | -14.76M | -5.96M | -28.06M | -23.51M | -33.86M | -24.31M | -31.95M | -24.36M | -21.97M |
| Diluted EPS | - | - | - | -0.62 | -0.26 | -0.32 | -0.41 | -0.40 | -0.42 | -0.42 | -0.25 | -0.30 | -0.11 | -0.51 | -0.38 | -0.55 | -0.39 | -0.51 | -0.39 | -0.35 |
| R&D Expense | 673.00K | 834.00K | 1.93M | 4.74M | 8.41M | 10.18M | 14.09M | 13.74M | 15.87M | 14.92M | 11.89M | 14.07M | 14.90M | 18.61M | 25.05M | 34.66M | 34.63M | - | 26.81M | 30.99M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 3.64M | 8.61M | 8.08M | 10.59M | 10.00M |
| Operating Income | -4.84M | -32.93M | -67.09M | -72.98M | -98.85M | -157.67M |
| Net Income | -6.78M | -32.67M | -63.06M | -58.29M | -68.99M | -113.62M |
| Diluted EPS | - | -1.39 | -1.52 | -1.32 | -1.28 | -1.83 |
| R&D Expense | 3.04M | 26.24M | 53.44M | 54.92M | 68.39M | 125.90M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 16.22M | - | 364.01M | 380.41M | 1.06B | 1.00B |
| Current Assets | - | - | - | 332.44M | 349.24M | 1.03B | 975.89M |
| Cash & Equivalents | - | 7.81M | - | 51.43M | 19.20M | 430.61M | 52.33M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | 0 | - | - | - | - |
| Total Liabilities | - | 9.23M | - | 43.27M | 36.06M | 38.73M | 44.74M |
| Current Liabilities | - | 3.18M | - | 16.51M | 13.03M | 17.46M | 25.00M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 25.30M | 24.54M | 23.02M | 22.14M |
| Total Equity | -7.94M | -14.64M | - | 320.74M | 344.35M | 1.02B | 956.82M |
| Shares Outstanding | - | - | - | 41.62M | 46.25M | 59.06M | 60.38M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.37M | -16.98M | -42.92M | -50.58M | -43.81M | -82.23M |
| Investing Cash Flow | 0 | -340.96M | 58.27M | -41.19M | -258.02M | -300.98M |
| Financing Cash Flow | 11.52M | 386.52M | 500.00K | 59.55M | 713.24M | 4.95M |
| Capital Expenditure | -0 | -1.48M | -6.45M | -1.85M | -359.00K | -1.04M |
| Free Cash Flow | -4.37M | -18.46M | -49.37M | -52.42M | -44.17M | -83.28M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | -905.4% | -779.0% | -902.9% | -933.6% | -1,576.7% |
| Net Margin % | - | -898.3% | -732.2% | -721.2% | -651.6% | -1,136.2% |
| ROE % | 46.3% | - | -19.7% | -16.9% | -6.7% | -11.9% |
| ROCE % | -37.2% | - | -19.3% | -19.9% | -9.5% | -16.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 18.30% | 11.19M | $205.78M |
| 2 | Blackrock Inc. | 10.03% | 6.13M | $112.82M |
| 3 | Prosight Management, Lp | 6.22% | 3.80M | $69.96M |
| 4 | State Street Corporation | 4.92% | 3.00M | $55.26M |
| 5 | FMR, LLC | 3.95% | 2.41M | $44.37M |
| 6 | Federated Hermes, Inc. | 3.85% | 2.35M | $43.27M |
| 7 | Point72 Asset Management, L.P. | 3.26% | 1.99M | $36.67M |
| 8 | Vanguard Capital Management LLC | 3.04% | 1.86M | $34.16M |
| 9 | TCG Crossover Management, LLC | 2.93% | 1.79M | $32.91M |
| 10 | Alyeska Investment Group, L.p. | 2.69% | 1.65M | $30.29M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for JANX
Janux Therapeutics (JANX) Stock May Look Overvalued After Its 110% Run - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQX2Jpa19WMXJkOUxJZE5SdXE3LW5FY1lJWmpSOVdQZXRzWUwxR01nREdoa3FFOWc3Vm54bkhkdGZGWDJtYXY1ZEFzdTg3TEdmMk52cGxJLWZ0YmwydC0zRnVqUWZrcEptN2tTazZYVWRpU01hazJhZW9UU0otQ2xqUTc0Vy1FbmxHc1Q0MG…
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNMTN6aFI0eWh0akthVzJpR1ZCSVhmTkUxZkFkblpGVUoxb2tiM0FuMWhicG8xMkJDM2tQdmM1UTJoWkRZaE54bWJ3REhNdzQ4RzhCb0xqRTQ1dEw1SEdyRUxNYURQUmt5c1RHNnpWLWlHX1AxY1lBSDV1Ym1rcGRyd0M1TWkzaWZ1dHpnbF…
JANX Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE9qSFB3RnJ5VnVrY1RJZ0RZVldMaGx5d2ZFNC12N1dFR0FBbkFuSGlNeGMwN3JwcWwwRjd0VjRYbTdCMGVBOHBkWUlFNzBGbGJnTFRydVA3Rk9rUnRTLUtXXzdzY0psR3Y4V3gxaTBONXJwUEx4ak5Bc2pB?oc=5" target="_blank">JAN…
Trading Systems Reacting to (JANX) Volatility - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxQV2RPdmxtd2ZDQVJ4RnJ6QVhVMzRDZFJydnRtY280b2l3VU5UUWFPX3hneVZwYzk5cHBqR0JiOGJOaTk5bkZaX1BQbTlFTFZGMmxQWlllSWFwaEN3OHNkaXlaNFdZRUU3ZVdadFNDQ3RDLTM2UmNNUWxmay1Ya2JuQ1pjbEUyRV9XMzdKUn…
H.C. Wainwright reiterates Janux stock rating, $45 target By Investing.com - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPS0NiTzVXckstM2NOUHJWZXRZZ0ozTFZxVmhDZ2J0TmE0Zy04dVc2ajVJWFRBbFhfbllKS2FGdW5jSUo2OEJXLUVKNGVKQVF6a1d6eVNWa1ItV29OVTdyTWtiSWY2eGRBSndOT0QxNm41eHVZdk50T1BtalhvbnE5MHFnV0xsWHhrdUMtRm…
Here's Why You Should Add JANX Stock to Your Portfolio Now - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPNGlVVndZREcwZmwwYWNzazNBekZhZDJKOFcwQy1NYmdnVGdCOEtQZjlvcWVUeno4SFNQdmQ5dHFZcmlaWUF0a0Y4VDFtTXhtX0xNajJJamJkaGVDN0xQOU9PVVg5RFVPV2thOTdROE1GVWI3MkxmeUVHUmpWUVUzV3NfamlnOWlCLUFYTm…
JANX — Frequently Asked Questions
What is the current share price of Janux Therapeutics, Inc. (JANX)?
As of 2026-10-23 16:27 PDT, Janux Therapeutics, Inc. (JANX) trades at $16.66 on NasdaqGM. Its 52-week range is $12.18 to $34.74.
What is the market capitalisation of JANX?
Janux Therapeutics, Inc. (JANX) has a market capitalisation of $1.02B on NasdaqGM.
What is the P/E ratio of JANX?
JANX trades at a trailing price-to-earnings (P/E) ratio of -10.16. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.09.
What is the return on equity (ROE) of JANX?
JANX has a return on equity (ROE) of -10.70%. Its return on capital employed (ROCE) is -16.15%.
Is JANX a good stock to buy?
This page provides a data-driven analysis of Janux Therapeutics, Inc. (JANX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.